Cancer Pipeline Portfolio

Health

adminDecember 11, 2020
6

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

Ingelheim, Germany & Basel, Switzerland: Acquisition will add another key dimension to Boehringer Ingelheim’s focus on patients with difficult-to-treat solid…
Read More »